Sodium cromoglycate-induced changes in the dose-response curve of inhaled methacholine in cystic fibrosis.
Fifteen patients with cystic fibrosis (CF) (aged 7 to 20 years, mean 12.3 years), all known to respond to a methacholine (MCh) challenge, had two MCh challenges preceded by an inhalation of normal saline on one occasion and sodium cromoglycate (SCG) on another. The variation in baseline FEV1 between the two days of the study was 10% or less in all patients. Four patients (27%) gained significant protection with SCG against this non-allergenic challenge and, in two patients, SCG completely blocked the effects of MCh. These results would support clinical studies of SCG in some patients with CF but not the widespread use of SCG in CF.
D000293:Adolescent; D000328:Adult; D002648:Child; D004205:Cromolyn Sodium / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008688:Methacholine Compounds / Q000008:administration & dosage*; D012129:Respiratory Function Tests; D012138:Respiratory Therapy
D008688:Methacholine Compounds; D004205:Cromolyn Sodium